|
[1] Chinese Society of Hepatology, Chinese Medical Association.Consensus on clinical management of hepatitis B virus-infected women of childbearing age[J]. J Clin Hepatol, 2018, 34 (6) :1176-1180. (in Chinese) 中华医学会肝病学分会.感染乙型肝炎病毒的育龄女性临床管理共识[J].临床肝胆病杂志, 2018, 34 (6) :1176-1180.
|
|
[2] HOU J, CUI F, DING Y, et al. Management algorithm for interrupting mother to child transmission of hepatitis B virus[J].Clin Gastroenterol Hepatol, 2018.[Epub ahead of print]
|
|
[3] FAN R, YIN X, LIU Z, et al. A hepatitis B-free generation in China:From dream to reality[J]. Lancet Infect Dis, 2016, 16 (10) :1103-1105.
|
|
[4] PI SN. Comparative analysis of clinical characteristics in pregnant women with chronic HBV infection between HBe Ag-negative and positive and the effect of antiviral therapy on maternal and fetal outcomes[D]. Guangzhou:Jinan University, 2018. (in Chinese) 皮赛男. HBe Ag阳性与阴性慢性HBV感染孕妇的临床特征及抗病毒治疗对母婴结局影响的对比分析[D].广州:暨南大学, 2018.
|
|
[5] WHO. Tenofovir reduces mother-to-child transmission of hepatitis B:New study[EB/OL]. (2018-08-08) [2018-11-14]http://www. who. int/hepatitis/news-events/hbv-mtct-tenofovir/en/.
|
|
[6] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016:A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3 (6) :383-403.
|
|
[7] LI FF, YUAN GS, ZHOU YP, et al. Analysis of clinical characteristics of 22906 gravidas with hepatitis B virus infection[J]. J Pract Med, 2016, 32 (8) :1335-1338. (in Chinese) 李飞凤, 袁国盛, 周元平, 等. 22906例孕妇乙型肝炎病毒感染状况的调查研究[J].实用医学杂志, 2016, 32 (8) :1335-1338.
|
|
[8] HE J, CHEN YP. Advance of influencing factors of mother to child transmission of HBV and anti-viral therapy during pregnancy[J]. Chin J Infect Dis, 2017, 35 (5) :311-314. (in Chinese) 何京, 陈友鹏.母婴乙型肝炎垂直传播影响因素与孕期抗病毒治疗进展[J].中华传染病杂志, 2017, 35 (5) :311-314.
|
|
[9] LI TY, HE J, LU YP, et al. Meta-analysis of mother-tochild transmission of HBV by amniocentesis[J]. J Mol Imaging, 2017, 40 (3) :299-303. (in Chinese) 李桃源, 何京, 卢永平, 等.羊膜腔穿刺对母婴HBV垂直传播的meta分析[J].分子影像学杂志, 2017, 40 (3) :299-303.
|
|
[10] PAPADAKIS MA, ELEFSINIOTIS IS, VLAHOS G, et al. Intrauterine-transplacental transmission of hepatitis B virus (HBV) from hepatitis B e antigen negative (precore mutant, G1896A) chronic HBV infected mothers to their infants. Preliminary results of a prospective study[J]. J Clin Virol, 2007, 38 (2) :181-183.
|
|
[11] MA LJ, MA YY, WANG LY, et al. Association of HBe Ag with intra-uterine transmission of HBV[J]. J Shandong Univ:Health Sciences, 2008, 46 (5) :528-530. (in Chinese) 马丽娟, 马玉燕, 王磊一, 等. HBe Ag与乙型肝炎病毒宫内感染的关系[J].山东大学学报:医学版, 2008, 46 (5) :528-530.
|
|
[12] SINGH AE, PLITT SS, OSIOWY C, et al. Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants[J]. J Viral Hepat, 2011, 18 (7) :468-473.
|
|
[13] SA-NGUANMOO P, TANGKIJVANICH P, THARMAPHORNPILAS P, et al. Molecular analysis of hepatitis B virus associated with vaccine failure in infants and mothers:A case-control study in Thailand[J]. J Med Virol, 2012, 84 (8) :1177-1185.
|
|
[14] LIU CP, ZENG YL, ZHOU M, et al. Factors associated with mother-to-child transmission of hepatitis B virus despite immunoprophylaxis[J]. Intern Med, 2015, 54 (7) :711-716.
|
|
[15] SCHILLIE S, WALKER T, VESELSKY S, et al. Outcomes of infants born to women infected with hepatitis B[J]. Pediatrics, 2015, 135 (5) :e1141-e1147.
|
|
[16] THILAKANATHAN C, WARK G, MALEY M, et al. Mother-to-child transmission of hepatitis B:Examining viral cut-offs, maternal HBsAg serology and infant testing[J]. Liver Int, 2018, 38 (7) :1212-1219.
|
|
[17] KUBO A, SHLAGER L, MARKS AR, et al. Prevention of vertical transmission of hepatitis B:An observational study[J].Ann Intern Med, 2014, 160 (12) :828-835.
|
|
[18] ZHANG H, PAN CQ, PANG Q, et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice[J]. Hepatology, 2014, 60 (2) :468-476.
|
|
[19] CHEN HL, LIN LH, HU FC, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV[J]. Gastroenterology, 2012, 142 (4) :773-781.
|
|
[20] BAI SF, LI P, CHEN G, et al. Clinical analysis of delayed immune failure of hepatitis B virus intrauterine infection[J]. J Chin Pract Diagn Ther, 2012, 26 (6) :623-624. (in Chinese) 白淑芬, 李萍, 陈庚, 等.迟发表现的乙型肝炎病毒宫内感染免疫失败临床分析[J].中华实用诊断与治疗杂志, 2012, 26 (6) :623-624.
|
|
[21] TERRAULT NA, LOK ASF, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67 (4) :1560-1599.
|
|
[22] LAMPERTICO P, AGARWAL K, BERG T, et al. EASL 2017clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67 (2) :370-398.
|
|
[23] LEI Y, LIU YY, LIU L, et al. Mother-to-child transmission of hepatitis B virus based on precision medicine[J/CD]. Chin J Liver Dis:Electronic Edition, 2017, 9 (3) :22-25. (in Chinese) 雷雨, 刘园园, 刘龙, 等.基于“精准医疗”理念的HBV母婴传播阻断[J/CD].中国肝脏病杂志:电子版, 2017, 9 (3) :22-25.
|
|
[24] CHAN HL, FUNG S, SETO WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBe Agpositive chronic hepatitis B virus infection:A randomised, double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1 (3) :185-195.
|
|
[25] PAN CQ, DUAN Z, DAI E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load[J]. N Engl J Med, 2016, 374 (24) :2324-2334.
|
|
[26] JOURDAIN G, NGO-GIANG-HUONG N, HARRISON L, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B[J]. N Engl J Med, 2018, 378 (10) :911-923.
|
|
[27] GREENUP AJ, TAN PK, NGUYEN V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus[J]. J Hepatol, 2014, 61 (3) :502-507.
|
|
[28] TSAI PJ, CHANG A, YAMADA S, et al. Use of tenofovir disoproxil fumarate in highly viremic, hepatitis B mono-infected pregnant women[J]. Dig Dis Sci, 2014, 59 (11) :2797-2803.
|
|
[29] MURAKAMI E, WANG T, PARK Y, et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy[J]. Antimicrob Agents Chemother, 2015, 59 (6) :3563-3569.
|
|
[30] AGARWAL K, BRUNETTO M, SETO WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection[J]. J Hepatol, 2018, 68 (4) :672-681.
|
DownLoad: